Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OTLK COMPANY HIGHLIGHTS
• Lead product candidate ONS-5010 / LYTENAVATM has potential to be first FDA-approved ophthalmic formulation of bevacizumab for use in multiple retinal indications 24
• Potential FDA Approval in 2022
• Targeting $13.1 Billion Global Ophthalmic Anti-VEGF Market1
• Potential for 12 Years of Market Exclusivity • Management Team with Extensive Clinical/Regulatory Ophthalmology & Drug Development Experience
OTLK Is in "BUY Zone" for BIG PROFITS with the next 3 catalyst events:
1) Ongoing Phase 3 pivotal trial with topline data expected Q3 2021
2) Biologics License Application (BLA) submission on Q4 2021.
3) BLA FDA Approval in 1Q 2022.
After "Phase 3" topline data, OTLK "can have" a Buyout, I think above $50.
OTLK New Corporate Presentation.
https://ir.outlooktherapeutics.com/static-files/d69330f5-ef3b-4f65-976f-1c687a038c75
Reconfirme all data and expectations.
My OTLK Price Target is $25 until 1Q 2022.
What will be Cathie Wood next prediction on ARK Funds?
Cathie Wood predicted Tesla.. then Cathie predicted Bitcoin.. she also predicted Genomics was the next huge breakout and severely undervalued..
I think for "ARKG" one of the next Cathie prediction it will be "OTLK" Outlook Therapeutics as it is a disruptive, innovative and undervalued company.
It's more of a question of WHEN Cathie takes a position in OTLK.
OTLK is:
a) Targeting $13.1 Billion Global Ophthalmic Anti-VEGF Market.
b) 12 years market exclusivity under new BLA.
c) Become first-line "step-edit" drug of choice.
d) Penetrate USA, EU, Australia and other developing markets.
BUY THE RUMORS SELL THE NEWS!
Today OTLK +17% Now at $2,36
Institutional Holders increasing their positions, new Institutional Holders buying, and also shorts closing their positions.
Lets squeeze the shorts.
My sugestion Bullish and Long for 1 or 2 years is OTLK
PRICE TARGETS: (Zacks+Nasdaq+TipRanks $5,00) ; (Barchart [Strong Buy]+ MarketBeat+CNN+WallStreetZen $6,00) ; Yahoo $4,88 ; MarketWatch $6,00/$5,00/$3,50) COVERTURE: Ladenburg Thalmann $9,00 ; Oppenheimer $12,00 Outperformer
Institucionais Sabby Managment, Vanguard, Armistice, Geode Capital, Two Sigma.
https://ir.outlooktherapeutics.com/.../a08b36df-0cdb-4c11...
1. Pivotal phase 3 data due July/August timeframe
2. They have enough cash to get through filing BLA for FDA Approval (in Q4) after data release.
3. They are continuing negotiations with potential partners, and believe the cash they now have gives them a much better position to that end.
These are the only relevant issues through the EOY. Beyond that while awaiting FDA approval, they will either have a partnership deal, buyout offer, or will need to raise more money for marketing, distribution, sales etc. to go it alone, which the additional shares can and will be used for, such the need arise. If approved, ONS-5010 will become the first line drug of choice for payor-mandated “step edit” in the US for retinal indications, estimated to be a $13 billion dollar market, and growing significantly.
My investment and target OTLK 40.000 shares x $25 = $1.000.000
?BIG ALERT FOR $VXRT NEXT WEEK February 3, 2021
United we can with $VXRT the same we done this week with GME!
Buy 100 shares at Market Price on February 3, 2021
?Next week the BIG TRADE to invest on February 3, 2021 it will be $VXRT (VAXART).
"COVID19 VACCINE IN A PILL"
Vaxart’s oral vaccine is room temperature stable
? No refrigeration for storage – major cost & space savings
? No refrigeration for distribution – significantly simpler & cheaper, eliminates potential bottlenecks
? Can be shipped cheaply to any corner of the US or the Globe
A room-temperature stable pill: simpler and cheaper to distribute and stockpile than injectable vaccines.
The Phase 1 FDA Tests Results will be announced next week.
Also next week VAXART will be on February 3, 2021 in the event on New York Academy of Sciences.
On that event it will be there also present the keynote speakers:
Dr. Anthony S. Fauci from National Institute of Allergy and Infectious Diseases.
Moncef Slaoui from Operation Warp Speed.
https://www.nyas.org/events/2021/webinar-the-quest-for-a-covid-19-vaccine/
https://investors.vaxart.com/static-files/76ded565-e448-4d98-910c-f1ae3629789c
BIG ALERT BIG TRADE FOR $VXRT NEXT WEEK February 3, 2021.
"COVID19 VACCINE IN A PILL"
BUY 100 shares at Market Price on February 3, 2021
I’m IN with that movement to crush and squeeze de shorts,
we have on $VXRT 33% Short Volume.
United with help of WallStreetBets we can do the same they done with $GME.
Price Target $200
VAXART Distribution Agreement for Malaysia for COVID19 Vaccine in a Pill
https://www.theedgemarkets.com/article/widad-collaborates-rinani-market-covid19-vaccine-malaysia
KUALA LUMPUR (Dec 15): Widad Group Bhd is collaborating with Rinani Dynamic Sdn Bhd in the distribution, marketing and selling of the Covid-19 vaccine known as Vxa-Cov2-1 and other products developed by US-based Vaxart Inc in Malaysia.
In a filing with Bursa Malaysia, Widad said it had entered into a memorandum of collaboration (MoC) with Rinani, which is involved in the business of investment advisory services and other management consultancy activities.
Widad said Rinani on Nov 29 was appointed by Hong Kong-based Majoritas Global Ltd as its exclusive partner in Malaysia to present, discuss and negotiate with the relevant authorities and parties relating to terms and conditions for testing, evaluating, placing on the market, contracting, financing and purchasing of the vaccine and other products in Malaysia.
“Even though Widad may not have the prior experience to undertake the distribution of the vaccine, Widad will hire additional experience key personnel to mitigate the risks in due course,” it said.
Widad said the MoC shall be effective for a period of one year upon the execution by both parties hereto and may be mutually extended by both parties.
VAXART First Distribution Agrement
Widad Group collaborates with Rinani Dynamic to distribute, market and sell Vaxart’s Covid-19 vaccine tablet
https://www.thesundaily.my/business/widad-group-collaborates-with-rinani-dynamic-to-distribute-market-and-sell-vaxart-s-covid-19-vaccine-tablet-CI5648325
Widad is principally involved in construction activities and integrated facilities management services.
Rinani is the local representative in Malaysia for Nasdaq-listed Vaxart, with respect to its ongoing development of an oral based (tablet) Covid-19 vaccine named VXA-Cov2-1. The appointment of Rinani was made by Majoritas Global Limited, a company incorporated in Hong Kong, who in turn is Vaxart’s global representative for Malaysia.
VXA-CoV2-1 is a single-dose Covid-19 tablet vaccine candidate which Vaxart believes can be conveniently distributed and administered without the need for cold-chain storage and distribution.
Under the agreement, Rinani will be collaborating with Widad in the distribution, marketing and selling of the vaccine and other Vaxart products in Malaysia. Widad stated that it is ready to support Rinani Dynamics objective of ensuring that people of Malaysia would be among the first to receive Vaxart’s vaccine, when it receives the FDA and EUA clearance for commercialisation. The vaccine candidate is expected to be entering Phase II of clinical trials.
Widad managing director Datuk Mohd Rizal Mohd Jaafar said Widad is determined to support Rinani’s effort in pushing Vaxart’s vaccine in Malaysia, to ensure that the nation would have access to what could be the most practical and sustainable vaccine for a mass vaccination program.
“Vaxart’s vaccine’s two biggest merits is first, that it is designed to trigger mucosal immunity, which is the first line of defence against airborne viruses such as Covid-19, providing total protection from infection altogether and second, being in tablet form, makes it the most ‘user-friendly’ vaccine, creating a hassle free, painless experience, one which I feel the people would greatly appreciate and would be encouraged to take.”
What Level 2 platform did you use?
VXRT annouced they will go to 3 Conferences in September.
They will go because they now they will have very good news to show in this Conferences.
Vaxart, Inc. to Participate in September Virtual Investor Conferences
»H.C. Wainwright : 22 nd Annual Global Investment Conference - September 14 th –16 th
»Sachs Associates : 20 th Annual Biotech in Europe Forum - September 21 st – 24 th
»SVB Leerink: CybeRx Series: Vaccine Forum - September 23 rd & – 24 th SOUTH SAN FRANCISCO, Calif. , Sept.
3 Reasons Doctors Will Prefer Vaxart's Coronavirus Vaccine, and 1 Reason They Might Not
https://www.fool.com/investing/2020/08/13/3-reasons-doctors-will-prefer-vaxarts-coronavirus/
I am long on VXRT. I want to win big money.
I Strong Believe VXRT it will be above $100 until end of 2020 and until end of 2021 above $200.
See the example of NVAX at May 01, 2020 was at $16,41 and achieve $151 on July 20, 2020.
I do not sell VXRT below $200, neither before vaccine go to the market.
VXRT is the TESLA of Vacines.
TESLA is above $1.460 today.
Lets dream about this, Sometimes Dreams come true!
VXRT EOY Above $45
$MBRX WE ARE BACK!
“WHO KNOWS”, …if the reason of SEC, temporary suspension of $MBRX on NASDAQ during 10 days, might be related to some big biotech company wants to buy $MBRX?
Perhaps SEC wants to confirm, all information about the Potential Drug Candidate for Covid-19.
$MBRX have a great pipeline development, which included drugs for FDA approval for treatment of Acute Myeloid Leukemia, Skin Cancer, Brain Tumors, Pancreatic Cancer, and now also a Potential Drug Candidate for COVID-19.
Remember also on May 3, 2020 $MBRX announced that Dr. Richard Whitley join to its Science Advisory Board to guide its development strategy for WP1122 for the potential treatment of COVID-19 and other viral diseases.
Whitley it will be the key to FDA he invented remdesivir.
It wouldn't be a surprise to me, if it could happen something similar to $MBRX, like what happened this year to $FTSV.
$FTSV was Acquired on February 23, 2020 by Gilead ($GILD) for $4.9 Billion ($95.50 per share), and FTSV on October 23, 2019 she had a 52 Week low price of $5.53.
The future will tell if something is on the way!
$MBRX Earnings per share Surprise +500% ; 1Qtr 2020 -$0,02 ; Zacks estimate -$0,10 and and same period in 2019 -$0,14
KTOV realistic Price Target $3,50
Moleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020
https://content.equisolve.net/_f56b954a1ab665ab4d1540ad819d77cd/moleculin/news/2020-05-08_Moleculin_Announces_Intention_to_Adjourn_2020_171.pdf
$KTOV On May 6, 2020 Sabby Volatility Warrant Master Fund, Ltd, have 8,333,334 shares
(Statement of Ownership (sc 13g)
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14125318&RcvdDate=5/6/2020&CoName=KITOV%20PHARMA%20LTD.&FormType=SC%2013G&View=html
MBRX they don't want to do a reverse stock split, they have now Nasdaq Compliance (close price above $1,00 in 10 consecutive days).
MBRX received a Nasdaq notification informe MBRX is now with Nasdaq Compliance rules.
Also until July 2020 because Covid19, Nasdaq suspend for all companies the obligation to be with compliance rules.
Because all of this I strong don't believe a reverse stock split on MBRX this year 2020
Today April 30, 2020 MBRX have a Zacks Rank: "1-STRONG BUY" and a Average Price Target $3,50 in next 1 to 3 months.
Today $ONTX Zacks Rating (Next 1 to 3 months) is:
"1 - Strong Buy"
Average Price Target: $7,00
Let's go!
ALERT: $VXRT Vaxart announces it entered into an agreemnet with Emergent BioSolutions for the development and manufacturing of oral vacine for Coro
na Virus
TRIL TREND in Stockinvest
During next 3 month TRIL with 90% probability hold a price between 21,04 to 34,51 at the end of this period.
https://stockinvest.us/technical-analysis/TRIL
It will be great.
Today February 13, 2020 ONTX Price Targets:
Zacks $7,00
Yahoo Finance $6,10
Both of them much more higher them you tell in your post.
Zacks and Yahoo Finance are credible sources of financial information and Price Targets.
Who is the Information Source?
Trillium Is An Undervalued, Misunderstood Biotech With Significant Upside In 2020
Feb. 11, 2020 3:23 PM ET Trillium Therapeutics Inc. (TRIL)
Terry Chrisomalis
Biotech Analysis Central
Actionable ideas on small-large cap biotech stocks through deep analysis.
https://seekingalpha.com/article/4323234-trillium-is-undervalued-misunderstood-biotech-significant-upside-in-2020?utm_source=dashboard.stck.pro&utm_medium=referral
Trillium Therapeutics Announces Changes to Its Board of Directors
Mr Paul Walker is appointed to the Board of Directors and Dr. Ali Behbahani has been appointed as a Board Observer, both are from New Enterprise Associates.
Dr. Robert Uger, Trillium’s Chief Scientific Officer has resigned from the Board of Directors effective February 6, 2020.
https://ir.trilliumtherapeutics.com/press-releases/press-release-details/2020/Trillium-Therapeutics-Announces-Changes-to-Its-Board-of-Directors/default.aspx
BOSTON CD47/SIRPa Summit 18–19 March 2020
March 19, 2020 at 9:10 PRESENTATION:
An Insight into Trillium Therapeutics’ Progress and What’s To Come.
SPEAKER: Yaping Shou
Chief Medical Officer
Trillium Therapeutics
Dr. Yaping Shou is the Chief Medical Officer of Trillium Therapeutics, a clinical-stage immune-oncology company developing innate immune checkpoint inhibitors. She has close to 20 years of industry experience spanning clinical development and translational medicine, with a strong focus in oncology. She most recently served as Executive Medical Director with Takeda Pharmaceuticals, and prior to joining Takeda, she held several clinical development positions with increasing responsibilities at Novartis Pharmaceuticals and GlaxoSmithKline.
She received her MD from Zhejiang University School of Medicine and her PhD in Cellular and Molecular Biology from Drexel University College of Medicine and of University Pennsylvania.
She also conducted postdoctoral studies in the Genetics Genetics Branch at the National Cancer Institutes.
$TRIL Key investors in the Offering included the Company’s existing significant shareholder New Enterprise Associates, as well as new investors:
Boxer Capital,
Logos Capital,
Vivo Capital,
Venrock Healthcare Capital Partners (Rockefeller Group)
among others.
I think $TRIL will achive:
$5 end of January 2020;
$10 end of February 2020 ;
$15 to $20 end of March 2020 (Because the CD47 Summit in Boston March 18-19, 2020)
BIOPHARMA STRATEGIES by TRIL CEO Jan Skvarka
He knows how to bring value to TRIL shareholders
https://www.bain.com/contentassets/100e20fbe19f43c38266df4eb44b0e1b/in_vivo_building_a_fully_integrated_biotech_company.pdf
$TRIL have 3 Year High at $13,30 ; 5 Year High at $29,92
Let's make a $TRIL "NEW LIFETIME HIGH" !
Let's go guys!
Thank good I sell SRRA on 31/Dec/2019 and bought TRIL in same day.
Great decision I take.
TRIL on 31/Dec/2019 was at $1.03 and today close at $4,22
I think TRIL achive higher price then FTSV.
I belive End Of Year at $65
Above $5 a lot of Funds, ETF, and Institucionals they will by much more.
AXSM in Jan 2019 was at $2 and achived $100
This can append also to TRIL
ROCKFELLER GROUP bought more TRIL shares and now have 5.3M shares is 9,95% of TRIL, through Venrock Healthcare Capital.
Who will be the next "BIG PLAYER" to buy TRIL?
ValueEngine upgraded shares of Trilium Therapeutics (NASDAQ:TRIL) from Hold to a Buy rating in last research note released on January 13, 2020
TRIL will achive more than $45